Stroke Prevention & Atherosclerosis Research Centre
London, Ontario, N6G 2V4, Canada
NCT Number: NCT03398889
Patients attending stroke prevention clinics and a premature atherosclerosis clinic at University Hospital in London, ON, Canada were recruited to the study. They completed a dietary questionnaire, provided stool samples and had blood drawn to measure plasma levels of metabolites produced by the intestinal bacteria.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
London, Ontario, N6G 2V4, Canada
Patients were phenotyped by their residual score in linear multiple regression with measured carotid plaque burden as the dependent variable and coronary risk factors were predictors. The residual score essentially represents the distance off the regression line of predicted plaque. They were grouped into three categories: Unexplained atherosclerosis (with more plaque than predicted by risk factors; residual score >2); Explained (the amount of plaque predicted by risk factors, residual score >-2 and <2); and Protected (less plaque than predicted by risk factors, residual score <-2).
DNA was extracted from stool samples in the lab of Dr. Allen-Vercoe at University of Guelph. RNA makeup of the intestinal microbiome was assessed in the lab of Dr. Gregory Gloor at Western. Plasma levels of trimethylamine n-oxide, p-cresylsulfate, hippuric acid, p-cresyl glucuronide, pheny acetyl glutamine and phenyl sulfate were measured by ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry in the lab of Dr. Bradley Urquhart at Western.
Nutrient intake over the past year was calculated at the Harvard School of Public Health from the 131 item self-reported and semi-quantitative Harvard Food Frequency Questionnaire (FFQ).
Estimated glomerular filtration rate was calculated from the Chronic Kidney Disease Epidemiological (CKD-EPI) equations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
plasma levels of metabolites
Harvard food frequency questionnaire
amplification and sequencing of 16S rRNA gene variable regions in stool samples
Time frame: Day 1
Plasma levels of trimethylamine n-oxide, p-cresylsulfate, hippuric acid, p-cresyl glucuronide, pheny acetyl glutamine and phenyl sulfate
Time frame: Day 1
Amplification and sequencing of 16S rRNA gene variable regions
Time frame: Day 1
Nutrient analysis from food frequency questionnaire
Time frame: Day 1
eGFR from CKD-EPI equations
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001204
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT02311335
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT07295366
Acute Stroke, Arterial Occlusive Diseases
Xuzhou, Jiangsu, China
View Trial DetailsNCT07615166
Arterial Occlusive Diseases, Arteriosclerosis
Bridgewater, New Jersey, United States
View Trial Details